SMT Completes Enrolment of Cruz HBR Registry to Further Evaluate the Safety and Efficacy of Supraflex Cruz in High Bleeding Risk Patients – IT News…

SMT Completes Enrolment of Cruz HBR Registry to Further Evaluate the Safety and Efficacy of Supraflex Cruz in High Bleeding Risk Patients Sahajanand Medical Technologies Pvt. Ltd. (SMT) (BusinessWire India) 2020-11-04 Business Wire India

Release summary points

SMT is a global medical device company committed to making advance medical technologies accessible to everyone around the world. With a presence in over 75 countries, SMT has achieved recognition from the Government of India for its tremendous contributions in the field of Cardiovascular healthcare. SMT has also led the development of innovative biodegradable polymer coating technology in coronary stent system. SMT will continue the journey to healing hearts around the world by creating a healthcare future promising for everyone. About Supraflex Cruz

Cruz design provides physicians an access to difficult and tortuous lesions which were very challenging in their practice. The stent retains all the benefits of the Supraflex stent or the previous Supra Family of stents, viz, Ultrathin strut thickness (60 microns for all diameters and lengths), blend of proprietary biodegradable polymers to release the drug, very thin layer of polymers, high radial strength, low crossing profile. The Supraflex Cruz has a very large and extensive size matrix. 1 set consist of 88 skus and covers diameters from 2.0 to 4.5 and lengths from 8 mm to 48 mm. This size matrix ensures that the physician and the patient does not need to make any compromise of accommodating a shorter or a longer stent inside the coronaries. About CERC

The CERC is a unique Contract Research Organization based in Massy, France, and presided by four medical directors, Dr. Marie-Claude Morice, Dr. Philip Urban, Dr. Davide Capodanno and Dr. Philippe Garot. The CERC was created with the aim of establishing a reputable high-quality dedicated CRO in Europe. Its objectives are to underpin European clinical trials and academic leadership, act as a global CRO and support young scientific leaders. The prestigious members of the CERCs Medical Advisory Council provide unparalleled guidance and expert support in a broad range of clinical trials dedicated to the assessment of interventional coronary and peripheral revascularization, structural and valvular heart disease treatments and adjunctive pharmacology. The CERC has an excellent track record in regulatory guidance, trial design, global study management and monitoring, CEC/DSMB coordination, core-lab activities for pre- and post- market drug and device trials. The CERCs industrial partners attach great importance to finding cost-effective models which do not compromise quality. The CERC has established a network of structures (CERC Asia, CERC Deutschland) in order to achieve this objective.

Tejaswini Kamalkar SMT +91-8291371332/9930456453 tejaswini.kamalkar@smt.in

Original post:
SMT Completes Enrolment of Cruz HBR Registry to Further Evaluate the Safety and Efficacy of Supraflex Cruz in High Bleeding Risk Patients - IT News...